Evaluating pediatric ureteropelvic junction obstruction: Dynamic magnetic resonance urography vs renal scintigraphy 99m-technetium mercaptoacetyltriglycine

Table 1 Characteristics of the entire study cohort, n (%)

	Entire cohort, n = 126	Scintigraphy MAG-3 only, n = 28	DMRU only, n = 54	Scintigraphy MAG-3 + dMRU, n = 40	P valuea
Sex					0.837
M	88 (70)	18 (64)	38(70)	28 (70)
F	38 (30)	10 (36)	16 (30)	12 (30)
Age at diagnosis, months	22 (8-112)	8 (4-70)	29 (8-119)	30 (14-127)	0.0471
Diagnosis
Prenatal	83 (66)	18 (64)	30 (55.5)	31 (77)	0.146
Postnatal	43 (34)	10 (36)	24 (44.5)	9 (21.5)
Associated anomalies					0.0476
Duplication of urinary system	3 (2.4)	0	3 (5.5)	0
Ureterocele	0	0	0	0
Single kidney	2 (1.6)	0	1 (2)	1 (2.5)
Horseshoe kidney	1 (0.8)	0	1 (2)	0
Vesicoureteral reflux	3 (2.4)	0	0	3 (7.5)
Pyelonephritis	21 (17)	2 (7)	12 (22)	7 (17.5)	0.241
Urinary stones	3 (2.4)	1 (4)	1 (2)	1 (2.5)	0.999
Follow-up, months	11 (3-23)	8 (3-27)	11 (4-19)	12 (5-20)	0.966

^aP value: Common presentation of ureteropelvic junction obstruction in the entire study cohort (P < 0.05 was considered statistically significant).

Values are presented as median (interquartile range) or n (%), as appropriate. dMRU: Dynamic contrast-enhanced magnetic resonance urography; F: Female; M: Male; MAG-3: 99m-technetium mercaptoacetyltriglycine.